Bull of the Day: Neurocrine Biosciences (NBIX)

With a strong financial position, we believe Neurocrine Biosciences (NBIX) is in an outstanding position to build shareholder value over the next several years.

The company exited the third quarter with $130 million in cash and receivables, with the potential to earn several hundred million more as clinical development progresses. The company’s dramatically improved financial position affords management the opportunity to push forward the development of internal pipeline candidates, including VMAT-2, as well as in-license new pre-phase II molecules within the company’s core CNS focus.

We recommend accumulating the stock at today’s price, up to our $12 target.

By Jason Napodano

NEUROCRINE BIOS (NBIX): Free Stock Analysis Report

About Zacks Investment Research 1766 Articles

Zacks Investment Research is one of the most highly regarded firms in the investment industry. In 1978 Zacks originated the concept of utilizing earnings estimates revisions to make profitable investment decisions. Zacks offers multiple investment products and services to help investors achieve superior returns.

Visit: Zacks.com

Be the first to comment

Leave a Reply

Your email address will not be published.